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ABSTRACT: 
Ectonucleotide triphosphate diphosphohydrolase-1 (ENTPD-1; CD39), a transmembrane enzyme 
expressed on platelets, leukocytes, and endothelial cells, is capable of hydrolyzing the 
prothrombotic purinergic signaling molecules adenosine triphosphate (ATP) and adenosine 
diphosphate (ADP) to adenosine monophosphate (AMP), which is then converted to adenosine 
by ecto-5'-nucleotidase (CD73).  Through this mechanism of action, CD39 and CD73 are 
capable of affecting ADP-dependent platelet activation and recruitment necessary for 
propagation of a growing thrombus following vessel injury.  Previous work by our laboratory has 
shown that transgenic over-expression of human CD39 (hCD39; CD39-TG) in mice results in 
greatly prolonged time to vessel occlusion compared to wildtype (WT) littermates.  This 
previous work did not specify whether CD39 over-expression on the cellular components of the 
blood or that on the endothelium was responsible for the protection against thrombus formation.  
In this study, we propose that the CD39-mediated thromboprotection results from over-
expression of CD39 on bone marrow-derived cellular components of the blood.  In addition, we 
show that it is possible to transfer this protection between genotypes by utilizing both bone 
marrow transplantation from an animal over-expressing CD39 to a wildtype animal and by 
infusion of platelets from a transgenic to a wildtype animal. 
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INTRODUCTION: 
According to data from the United States Center for Disease Control, cardiovascular 
disease is the leading cause of morbidity and mortality in the United States and in the Western 
World.
1
  A large portion of these deaths result from myocardial infarction (MI/heart attacks) and 
cerebrovascular ischemic incidents (strokes) caused by coagulation of blood and the formation of 
an occlusive thrombus.  These occlusive thrombi form in response to vascular injury and restrict 
the flow of oxygen and nutrient-rich blood to downfield tissue, which can lead to death of the 
tissue if blood flow is not promptly resumed.  In response to cellular injury of vessels and 
exposure of the sub-endothelial matrix, various signaling cascades converge and result in a local 
increase purinergic signaling molecules, specifically the pro-thrombotic and pro-inflammatory 
molecules adenosine triphosphate (ATP) and adenosine diphosphate (ADP).
2
  These have been 
shown to activate platelets, a cellular component of the blood and one of the key mediators of 
thrombus formation, via the P2Y1 and P2Y12 receptors.
3,4
  Once activated, platelets undergo a 
shape change and recruit other platelets to the site of injury by releasing ADP.
5,6
  This ADP can 
then activate additional platelets, leading to a feed-forward cascade working to propagate the 
growing thrombus.
6 
 Because of this phenomenon, the ectoenzyme ectonucleotide triphosphate 
diphosphohydrolase-1 (ENTPD-1; CD39) is in a unique position to modulate platelet activation 
and thus thrombosis. 
CD39 is a 70 – 100 kDa transmembrane protein expressed on endothelial cells and 
various blood cellular components, specifically platelets and leukocytes .
7,8
  CD39 hydrolyzes 
the prothrombotic purinergic molecules adenosine triphosphate (ATP) and adenosine 
diphosphate (ADP) to adenosine monophosphate (AMP).
7
  Ecto-5’-nucleotidase (CD73) can 
then hydrolyze AMP to the antithrombotic, anti-inflammatory molecule adenosine (ADO) 
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(Figure 1).
9
  Previous work conducted in our laboratory has shown that global transgenic over-
expression of human CD39 (hCD39) in mice can prolong the time to complete cessation of flow 
by an occlusive thrombus in a large conduit artery following ferric chloride-induced injury of the 
vessel when compared with the same model of injury in wildtype (WT) mice (Figure 2).
10 
 As 
CD39 is expressed on both endothelium and blood cells, these studies did not offer insight into 
the specific cell populations responsible for the thromboprotection.   
Here we demonstrate that circulating CD39 found on blood cells plays a larger role in the 
prevention of formation of an occlusive thrombus than the CD39 found on the vasculature.  In 
addition, we have shown that it is possible to modulate thrombus formation in wildtype mice by 
altering the levels of CD39 found on their circulating cells via bone marrow transplants and 
transfusions of cells purified from whole blood. 
 
METHODS: 
Transgenic Mice: 
Transgenic mice over-expressing hCD39 were generated and graciously supplied by our 
collaborators.
11 
 The human CD39 transgene is expressed from the mouse H-2K
b
 promoter 
resulting in global expression of CD39 in these mice.  CD39-TG mice were backcrossed for 
more than 10 generations onto the C57-Black 6 background and compared with littermate 
controls.  The investigations described conform to the Guidelines
 
for the Care and Use of 
Laboratory Animals of the National Institutes of Health and were approved by The Ohio State 
University Institutional Animal Care and Use Committee. 
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In Vivo Arterial Thrombosis: 
Ferric chloride (FeCl3)-induced carotid artery thrombosis was used for these experiments.
12  
WT 
or CD39-Tg mice were anesthetized with ketamine (55 mg/kg body weight) and xylazine (15 
mg/kg body weight).  Atropine (0.05 mg SC) was administered to reduce airway secretions.  
Animals were intubated and ventilated with room air (tidal volume 250 μl, 150 breath/min) with 
a mouse respirator (Harvard Apparatus, Holliston, MA). Rectal temperatures were maintained at 
37
o
C by a thermo-regulated heating pad.  The left common carotid artery was gently dissected, a 
flow probe placed on the artery (MA0.5PSB; Transonic Systems; Ithaca, NY) and blood flow 
measured with a pulsed doppler flow system.  After obtaining baseline flow recordings, carotid 
artery injury was induced by application of filter paper saturated with 10% FeCl3 solution on the 
adventitial surface proximal to the flow probe for 3 minutes.  The flow as a percent of baseline 
and the time to thrombotic occlusion (blood flow of 0 ml/min) was measured from the placement 
of the FeCl3 saturated filter paper.  The operator was blinded to the animal genotype and any 
drug treatment during all experiments.  Animals were re-anesthetized as needed and at each hour 
under anesthesia, animals were administered normal saline intraperitoneally.  
 
Ablation of Bone Marrow: 
Mice to receive bone marrow transplants were subjected to treatment with ultraviolet (UV) 
radiation from an RS-2000 Biological Irradiator (RAD-Source, Suwanee, GA) in order to ablate 
native bone marrow.  Twenty-four hours before transplant was to occur, mice were placed inside 
the irradiator for 5 minutes and received 100 cGy per minute.  After 4 hours, mice were 
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subjected to a second dose of radiation for 4 minutes (100 cGy per minute).
13
  Mice were 
immediately placed on Baytril water treatment to help prevent infection.
14
   
 
Bone Marrow Isolation and Transplant 
Donor mice were sacrificed under sedation of ketamine (55 mg/kg body weight) and xylazine 
(15 mg/kg body weight).  The long bones of the hind leg were then removed and stripped of 
connective tissue before being snapped at the knee.  The epiphysis were removed with surgical 
scissors and a 27 gauge needle was used to flush 3 mL of RPMI buffer (CellGro, Manassas, VA) 
through the long bones to harvest the marrow.  Bone marrow was spun at 300x g for 5 minutes at 
4 degrees Celsius.  Supernatant was discarded and pellet was resuspended in 10 mL of 1x red 
blood cell (RBC) lysis buffer (BioLegend, San Diego, CA) for 5 minutes, after which 10 mL of 
RPMI buffer was added and the solution was centrifuged at 300x g for 5 minutes at 4 degrees 
Celsius.  Pellet was resuspended in RPMI with 5% (w/v) fetal bovine serum (FBS) to give a final 
concentration of 1 x 10
6
 to 5 x 10
6
 cells per 100 μL of buffer.13,14 
 Mice received bone marrow transplant approximately 24 hours after last dose of radiation 
was received.  Mice were placed in a restraining device which allowed access to the tail.  100 μL 
of cell-RPMI solution was injected via the tail vein with a 28 gauge U-100 insulin syringe 
(Becton Dickinson and Company, Franklin Lakes, NJ).
 
 
Visualization of Thrombus Formation In Vivo: 
For visualization of thrombus formation, mice were injected intravenously (via the tail vein) with 
5 μL of a 100 μM solution/gram of body weight of the cationic lipophilic dye 3,3'-
dihexyloxacarbocyanine iodide (DICO6(3)) ten minutes prior to application of FeCl3.
15
  The 
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carotid artery was continuously video recorded using a Leica M165 FC fluorescent 
steromicroscope equipped with Hamamatsu ORCA-R
2
 Digital CCD camera for 30 minutes.   
 
Platelet Isolation and Injection: 
Donor mice were anesthetized with ketamine (55 mg/kg body weight) and xylazine (15 mg/kg 
body weight).  Blood was then collected via closed chest cardiac puncture with a 23 gauge 
syringe into a 3 mL syringe containing 200 μL Acid-citrate-dextrose.16  Whole blood was 
centrifuged at 300x g for 8 minutes.
17
 Platelet rich plasma (PRP) supernatant was aspirated and 
mixed with 1 mL Tyrode’s Buffer containing 1 mM CaCl2 and 2 μL of 0.5 mg/mL prostaglandin 
(PGE-1).
16,17
  Erythrocyte-rich pellet was discarded.  If the PRP appeared to have a reddish hue, 
it was determined that the blood cells had hemolyzed and sample was discarded.  PRP-Tyrode’s 
solution was centrifuged again at 300x g for 4 minutes.  Platelets were then washed by aspirating 
1 mL of supernatant and adding 1 mL of fresh Tyrode’s buffer with calcium and 2 μL of 0.5 
mg/mL PGE-1.
17
  Resulting solution was centrifuged at 300 X g for 4 minutes.  Supernatant was 
discarded and platelet-rich pellet was resuspended in 100 μL sterile phosphate-buffered-saline 
(PBS).  If visualization of clot was desired, DIOC6 dye was mixed with platelet solution and then 
injected via the tail vein with a 28 gauge U-100 insulin syringe (Becton Dickinson and 
Company, Franklin Lakes, NJ) 15 minutes prior to application of FeCl3. 
 
Flow Cytometric Analysis: 
Whole blood was obtained via tail bleed of WT or CD39-TG mice.  All antibodies were obtained 
from EMFRET Analytics GmbH & Co. KG (Eibelstadt, Germany) and eBioscience (San Diego, 
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CA).  Fluorescence-activated cell sorting (FACS; LSRII, Becton Dickinson and Company, 
Franklin Lakes, NJ) was used with antibodies to hCD39 in order measure the level of CD39 on 
leukocytes to determine if blood was “transgenic” or “wildtype” regardless of genotype of 
animal from which it was obtained.  Antibodies to CD45 were also used as a control to ensure 
cells being analyzed from hCD39 were blood cells derived from bone marrow.  Negative 
controls were used to inquire if there were differences between the CD39-TG and WT animals at 
baseline.    
 
Data Analysis: 
The results of experiments were analyzed by several statistical methods using standard software 
(GraphPad Prism, version 4.0). Results were expressed as mean ± standard error of the mean. 
For comparison between
 
2 groups, significance was determined by unpaired Student t test. For 
comparison
 
of multiple groups, multifactorial ANOVA with post-hoc comparison of the means 
with Bonferroni correction used to determine statistical significance. For all
 
evaluations, 
probability values of p < 0.05 were considered significant. 
 
RESULTS:   
Transplant of hCD39-Over-expressing Bone Marrow resulted in production of hCD39-over-
expressing blood cellular components 
In order to ensure successful engraftment of bone marrow transplant and subsequent 
production of genotypically correct cells, complete blood count (CBC) and Fluorescence-
activated cell sorting (FACS) analyses were performed on whole blood obtained from animals 
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approximately 60 days after transplant of bone marrow.  CBCs confirmed that levels of white 
blood cells, red blood cells, and platelets had returned to baseline levels and did not significantly 
differ between groups (Table 1 and Figure 3) but it was unknown if bone marrow-derived blood 
cells were over-expressing hCD39, which would confirm successful engraftment of CD39-TG 
bone marrow and subsequent production of CD39-TG blood cells.  To confirm successful 
engraftment and hematopoesis, whole blood was obtained and centrifuged to isolate leukocytes, 
which were washed and then incubated with antibodies to hCD39 and CD45 in order to test for 
the presence of the enzyme. 
 Pseudo-color plots show the comparison between the fluorescence of control, unstained 
cells, cells which had been incubated with an antibody to hCD39, and cells which had been 
incubated with two antibodies, one to hCD39 and one to CD45 (Figures 4a – 4e).  
Histogram plots also give the relative counts of cells with respect to phycoerythrin (PE) 
fluorescence (Figure 5).  Control cells showed no significant difference in geometric mean of a 
histogram plot between the two groups (WT  CD39-TG: 7.2 ± 2.0, n=3;  CD39  TG: 8.7 ± 
1.3, n=3;  p = ns, Figure 5).  When incubated with antibodies to CD39 and CD45, however, there 
was a significant increase in the geometric mean of the CD39-TG  WT group, compared to the 
WT  CD39-TG group (WT  CD39-TG: 183.0 ± 20.5, n=3;  CD39-TG  WT: 522.7 ± 35.3, 
n=3;  p < 0.005, Figure 5). 
 
Transplant of WT Bone Marrow resulted in production of WT blood cellular components 
Similar to what was described above, CBC and FACS analysis was employed to 
determine if successful engraftment of bone marrow had taken place in CD39-TG animals which 
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received WT bone marrow.  No significant differences were seen when comparing the CBC 
results of the WT into CD39-TG bone marrow transplant group to baseline levels in WT and 
CD39-TG mice nor when comparing the two groups of bone marrow transplants.  Pseudo-color 
plots of the FACS data show very little difference between the control, unstained cells and those 
cells incubated with anti-hCD39 (Figure 4f – 4j).  Analysis of the geometric means generated by 
the histogram plots shows significantly less fluorescence in the WT into CD39-TG group 
compared to the CD39-TG into WT groups when incubated with both antibodies to hCD39 and 
CD45 (WT  CD39-TG: 183.0 ± 20.5, n=3;  CD39-TG  WT: 522.7 ± 35.3, n=3;  p < 0.005, 
Figure 5). 
 
Transplant of hCD39-Over-expression Bone Marrow Mediates Resistance to Arterial 
Thrombosis 
To examine the role of CD39 on blood cells and endothelium individually, bone marrow 
transplant experiments were performed.  WT mice were irradiated and received bone marrow 
from CD39-TG mice, thus allowing them to maintain basal levels of CD39 on endothelium but 
over-express CD39 on bone marrow-derived blood cellular components such as platelets and 
leukocytes.  Conversely, a group of CD39-TG mice were irradiated and received bone marrow 
from WT mice, allowing these mice to maintain over-expression of CD39 on endothelium, but 
WT levels of CD39 on bone marrow derived blood cellular components.  After engraftment of 
bone marrow was confirmed via FACS analysis, FeCl3 – induced vascular injury experiments 
were performed and the time to thrombosis was measured.   The time to complete occlusion of 
the vessel was markedly prolonged in the WT animals which received CD39-TG bone marrow, 
when compared to baseline times for WT mice.  (CD39-TG  WT: 102.00 ± 7.71 min, n=5; 
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Baseline WT: 12.69 ± 2.19 min, n = 4; p<0.005).  In the CD39-TG mice which received WT 
bone marrow, the time to vessel occlusion did not differ significantly from WT experiments.  
(WT  CD39-TG: 13.14 ± 0.41 min, n=5; Baseline WT: 12.69 ± 2.17 min, n=5).  (Figure 6). 
 
hCD39-Over- expressing Platelets Mediate Resistance to Arterial Thrombosis 
To test our hypothesis that cellular components of the blood were responsible for 
thromboprotection seen in the CD39-TG animals, we designed experiments that involved 
transfusing cells purified from a CD39-TG animal into a WT animal (CD39-TG  WT), using 
transfusion of WT cells into WT animals (WT WT) as a control.  For this study, the individual 
cell type to be tested was platelets, due to their role in thrombus formation.  WT animals, which 
received approximately 7 million cells isolated from the whole blood of CD39-TG animals, 
showed significantly prolonged time to vessel occlusion following injury of the carotid artery 
with FeCl3 ( WT baseline: 12.69 ± 2.17 min, n=5; CD39-TG  WT: 179.90 ± 34.70 min, n=5; 
WT  WT: 11.21 ± 1.58 min, n=5; p <0.005) (Figure 7). 
 
hCD39-Mediated Resistance to Arterial Thrombosis is Calcium Dependent 
A second group of platelet transfusion experiments in which calcium was omitted from 
the isolation and wash buffer yielded a surprising result.  When calcium was omitted from the 
Tyrode’s buffer used to isolate and wash the platelets to be transfused, the thromboprotection 
seen before when platelets from a CD39-TG mouse were transfused into a WT mouse 
disappeared and the times to thrombosis showed no significant difference from baseline WT 
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mice (CD39-TG  WT: 9.43 ± 0.83 min, n=4; WT  WT: 11.53 ± 0.62 min, n=4; WT 
baseline: 12.69 ± 2.17 min, n=5; p = ns) (Figure 8). 
DISCUSSION: 
 Based on data collected from various experiments over the course of this project, we 
believe the protection resulting from over-expression of the ectoenzyme Ectonucleotide 
triphosphate diphosphohydrolase-1 (ENTPD-1; CD39) is primarily due to up-regulated levels of 
the enzyme on cellular components of the blood, not elevated levels on the endothelial cells of 
conduit arteries.  Using bone marrow transplants, we were able to focus the over-expression from 
global, to more tissue specific.  Wildtype mice who received bone marrow from a CD39-TG 
mouse began producing blood cells which tested positive for the hCD39 transgene.  Conversely, 
CD39-transgenic animals which received bone marrow from a wildtype mouse began producing 
blood cells which did not show expression of the hCD39-transgene.  Ideally, these experiments 
focused the expression to the bone marrow-derived blood cells, but not the endothelium in the 
CD39-TG into WT transplant mice; and in the endothelium, but not the bone marrow derived 
blood cells in the WT into CD39-TG transplant mice.  This assumption, however, requires 
further investigation for validation.  Recent studies have suggested that endothelial cells can 
originate from bone marrow progenitor cells and some groups claim to have found evidence for 
circulating bone marrow-derived endothelial cell progenitors.
18
  Experiments are currently 
underway in which the aorta and carotid arteries of transplant mice are being harvested to test for 
levels of hCD39 via western blot analysis compared to basal levels in the WT and CD39-Tg.  
Regardless, our results showing a markedly prolonged time to thrombosis in the CD39-TG  
WT animals, but not in the WT  CD39-TG animals strongly suggest that cellular components 
of the blood are primarily responsible for the thromboprotection.   
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Upon reaching the conclusion that over-expression of CD39 on cellular components of 
the blood was responsible for the prolonged time to thrombosis, our lab developed experiments 
to test the role played by individual cell types.  Due to the time constraints of this study, we 
determined it would only be possible to test the role of one type of cell, and as such, we chose to 
focus on platelets due to their well documented role in thrombosis and hemostasis.
19
  Data 
collected from the experiments performed suggest that CD39 expression on platelets play a key 
role in modulating thrombosis.  Simply by infusing transgenic platelets into a WT mouse, the 
time to thrombosis was significantly prolonged compared to untreated mice and  a control group 
in which WT mice which received WT platelets.  An important limitation of this study is that it 
remains unknown whether over-expression of CD39 on blood cells and platelets is simply 
preventative, i.e. the thromboprotection is only seen when the treatment occurs before vascular 
injury.  The question remains if CD39 has the potential to halt and/or even reverse the formation 
of an occlusive thrombus if administered after vascular injury has occurred.  Our laboratory is 
currently exploring different methods to determine if either soluble CD39 (apyrase from 
potatoes) or platelets isolated from the whole blood of a CD39-TG animal can modulate 
thrombosis if administered after vessel injury, and if so, how long after thrombosis they may be 
infused as an effective thrombolytic agent.   
With our conclusion that the cellular components of the blood in CD39-TG animals are 
responsible for protection against thrombus formation and our results that this protection is able 
to be transferred between genotypes via the use of one of those cellular components in CD39-TG 
platelets, we would like to investigate the roles that other cell types potentially play in CD39-
mediated thromboprotection.  Recent studies have suggested that leukocytes, specifically 
monocytes and neutrophils, play a significant role in thrombus formation.
20,21
  To test this 
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hypothesis in our model and to determine in CD39 over-expression on these cells can modulate 
resistance to thrombosis similar to what we have shown in platelets, our laboratory is currently 
carrying out experiments mimicking the procedure used in the platelet transfer described 
previously to transfuse leukocytes from a CD39-TG mouse into a WT mouse and observe the 
resulting change, if any, in the time to thrombosis.  Another area of interest is the presence of 
circulating monocyte-platelet aggregates which have been shown to indicate platelet 
activation.
22,23
  Our laboratory would like to use FACS analysis to investigate the difference 
between circulating monocyte-platelet aggregates ex vivo to help determine if CD39 expression 
on blood cells can reduce platelet activation, and thus, monocyte-platelet aggregates. 
Our result that thromboprotection transfer via platelets is calcium dependent, although 
interesting, may not appear to be surprising when the physical characteristics of the CD39 
enzyme are considered.  As a phosphohydrolase enzyme, one would expect the active site to 
contain a cation of some sort to stabilize the strong negative charge on the phosphate backbone.  
Previous studies have indeed shown that CD39 requires divalent metal cations for fully 
functional enzymatic activity.
24
  We believe that our results confirm this to be true by showing it 
is possible to transfer CD39-mediated thromboprotection between animals via platelets, but only 
when calcium is used in isolation and purification buffer.  In future studies investigating the roles 
of various other cell types the role of calcium will also be examined to see if the same calcium 
dependence holds true. 
An important limitation of this study is that all of the thrombosis experiments were 
performed on one model.  In an effort to validate our results and demonstrate that they are not 
method specific, experiments are underway to test the thromboprotective capabilities of CD39 in 
a Folts-like method of thrombosis with cyclic flow reductions.
25
  As the Folts method is known 
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to produce platelet-rich thrombi, we believe this will serve as an excellent model to validate our 
argument that CD39 found on platelets modulates protection against thrombus formation.
26,27
 
We believe our findings presented here hold potential for novel therapeutics in the future.  
As stated earlier, ADP is a prothrombotic signaling molecule and has been shown to activate 
platelets via interaction with the P2Y12 receptor.
2,3
  Common therapeutics to fight thrombus 
formation includes the drug clopidogrel, commonly known as Plavix, which acts via antagonistic 
interaction with the P2Y12 receptor.
28
 Although this treatment has been successful, there are 
patients who do not respond to clopidogrel due to genetic mutations in their P2Y12 receptors, 
rendering the treatment useless.
29
  Our findings presented here suggest an alternative route to 
preventing platelet activation and aggregation.  Instead of preventing activation of platelets with 
receptor antagonists, our data suggests that it might be equally effective to hydrolyze the 
signaling molecule ADP in order to prevent receptor engagement and subsequent activation. 
In the future, we would like to further investigate the role of specific cellular and non-
cellular components of the blood, including leukocytes, macrophages, granulocytes and 
microparticles.  Experiments are in progress to isolate leukocytes from whole blood obtained 
from CD39-TG animals and inject these cells into WT animals.  We would also like to confirm 
our finding that over-expression of CD39 on platelets modulates resistance to arterial thrombosis 
by using a genetic approach in which the transgene is expressed solely on platelets.  Investigators 
are currently working on generation of a “CD39 platelet-specific” over-expressing animal for use 
in our future experiments. 
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Table 1:  Complete blood count results from bone marrow transplant and untreated groups 
Parameter WT 
(n=5) 
CD39-TG 
(n=5) 
WT  CD39-TG 
(n=6) 
CD39-TG  WT 
(n=5) 
p 
White Blood Cells 
(K / μL) 
12.6 ± 1.2 9.1 ± 1.7 12.0 ± 1.4 12.9 ± 2.2 ns 
Red Blood Cells 
(K / μL) 
11.2 ± 0.3 9.5 ± 1.0 9.6 ± 0.2 
 
9.2 ±0.3 ns 
Platelets  
(K / μL) 
939.8 ± 172.8 1180.0 ± 180.3 862.0 ± 86.9 760.0 ± 61.7 ns 
No significant statistical difference between groups, please see Figure 3 for a graphical 
representation of data. 
 
FIGURES: 
Figure 1: 
 
Schematic of CD39/CD73 activity and purinergic receptor signaling overview. 
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Figure 2:   
2a: 
   
Baseline times to thrombosis for WT (12.69 ± 2.17 min, n = 5) and CD39-TG (665.0 ± 24.5 min, 
n = 3)  
2b: 
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Time plot showing percentage flow of initial following ferric chloride induced vessel injury 
(ferric chloride applied for 3 minutes starting at Time = 0) for WT and CD39-TG animals. 
 
Figure 3:   
 
 
 
Figure 3a: 
Graphical representation of White Blood 
Cell (WBC) counts.   
 
WT baseline: 12.6 ± 1.2 K / μL, n = 5;  
TG baseline: 9.1 ± 1.7 K / μL, n = 5;  
WT into CD39-TG: 12.0 ± 1.4 K / μL, n 
= 6 
CD39-TG into WT: 12.9 ± 2.2 K / μL, n 
= 5 
 
 
 
 
Figure 3b: 
Graphical representation of Red Blood 
Cell (RBC) counts.   
 
WT baseline: 11.2 ± 0.3 K / μL, n = 5;  
TG baseline: 9.5 ± 1.0 K / μL, n = 5;  
WT into CD39-TG: 9.6 ± 0.2 K / μL, n = 
6 
CD39-TG into WT: 9.2 ± 0.3 K / μL, n = 
5 
 
p = ns 
p = ns 
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Figure 3c: 
Graphical representation of Platelet cell 
counts.   
 
WT baseline: 939.8 ± 172.8 K / μL, n = 
5;  
TG baseline: 1180.0  ± 86.9 7 K / μL, n = 
5;  
WT into CD39-TG: 862.0 ± 86.9 K / μL, 
n = 6 
CD39-TG into WT: 760.0 ± 61.7 K / μL, 
n = 5 
 
 
Figure 4:   
 
 
 
 
Figure 4a: 
Pseudo-color plot showing 
leukocytes isolated from whole 
blood obtained from a WT 
animal which received CD39-
TG bone marrow.  These cells 
have not been incubated with 
any antibodies, they are serving 
as the negative control for the 
CD39-TG in WT group.  96.5 ± 
0.3% of cells in Q4, n = 3. 
p = ns 
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Figure 4b: 
Pseudo-color plot showing 
leukocytes isolated from whole 
blood obtained from a WT 
animal which received CD39-
TG bone marrow.  These cells 
have been incubated with an 
anti-hCD39 antibody.  27.7 ± 
3.3% of cells in Q4, 70.9 ± 
3.5% in Q1, n = 3. 
 
 
 
 
Figure 4c: 
Pseudo-color plot showing 
leukocytes isolated from whole 
blood obtained from a WT 
animal which received CD39-
TG bone marrow.  These cells 
have been incubated with an 
anti-hCD39 antibody as well as 
an antibody to CD45. n = 3. 
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Figure 4d: 
Pseudo-color plot showing an 
overlay of figures 4a and 4b.  
Unstained cells are shown in 
red and those incubated with 
anti-hCD39 are shown in blue. 
 
 
 
 
Figure 4e: 
Pseudo-color plot showing an 
overlay of figures 4a-4c.  Red 
are negative control cells, blue 
indicates cells stained with anti-
hCD39, and orange shows cells 
stained with both anti-hCD39 
and anti-CD45. 
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Figure 4f: 
Pseudo-color plot showing 
leukocytes isolated from whole 
blood obtained from a CD39-
TG animal which received WT 
bone marrow.  These cells have 
not been incubated with any 
antibodies, they are serving as 
the negative control for the WT 
into CD39-TG group.  91.3 ± 
6.1% of cells in Q4, n = 3. 
 
 
 
 
Figure 4g: 
Pseudo-color plot showing 
leukocytes isolated from whole 
blood obtained from a CD39-
TG animal which received WT 
bone marrow.  These cells have 
been incubated with an anti-
hCD39 antibody.  91.0± 7.0% 
of cells in Q4, 3.4 ± 2.5% in 
Q1, n = 3. 
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Figure 4h: 
Pseudo-color plot showing 
leukocytes isolated from whole 
blood obtained from a CD39-
TG animal which has received 
WT bone marrow.  These cells 
have been incubated with an 
anti-hCD39 antibody as well as 
an anti-CD45 antibody.  n = 3. 
 
 
 
 
Figure 4i: 
Pseudo-color plot showing an 
overlay of figures 4f and 4g.  
Unstained cells are shown in 
red and those incubated with 
anti-hCD39 are shown in blue. 
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Figure 4j: 
Pseudo-color plot showing an 
overlay of figure 4f – 4h.  
Unstained cells are shown in 
red, cells incubated with anti-
hCD39 are shown in blue, and 
cells incubated with both anti-
hCD39 and anti-CD45 are 
shown in orange. 
Figure 5: 
 
 
 
Figure 5a: 
Histogram plot for leukocytes obtained 
from whole blood which has not been 
incubated with any antibodies.  Geometric 
means:  WT  CD39-TG:  7.2 ± 2.0, n = 
3.  CD39-TG  WT: 8.7 ± 1.3, n = 3, p = 
ns. 
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Figure 5b: 
Histogram plot for leukocytes isolated 
from whole blood obtained from a CD39-
TG animal which received WT bone 
marrow.  Leukocytes have been stained 
with antibodies to hCD39 and CD45.  
Geometric mean: 183.0 ± 20.5, n = 3. 
 
 
 
Figure 5c: 
Histogram plot for leukocytes isolated 
from whole blood obtained from a WT 
animal which received CD39-TG bone 
marrow.  Leukocytes have been stained 
with antibodies to hCD39 and CD45.  
Geometric mean: 522.7 ± 35.3, n = 3. 
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Figure 5d: 
Histogram plot showing an overlay of figures 5a – 5c.  Orange is the control baseline, blue 
depicts WT  CD39-TG, and red depicts CD39-TG  WT. 
 
 
  
CD39-TG  WT, 522.7 ± 35.3. 
WT  CD39-TG, 183.0 ± 20.5 
p<0.005 
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Figure 6: 
6a:
 
Comparison of the times to thrombosis for bone marrow transplant (BMT) experiments versus 
baseline experiments.  WT baseline: (12.69 ± 2.17 min, n = 5), WT into CD39-TG BMT: (12.28 
± 4.54, n = 4), CD39-TG baseline: (665.00 ± 24.50 min, n = 3), CD39-TG into WT BMT: 
(329.70 ± 68.15, n = 4). 
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6b: 
 
Time plot showing percentage flow of initial following ferric chloride induced vessel injury 
(ferric chloride applied for 3 minutes starting at Time = 0) for WT in CD39-TG and CD39-TG 
into WT bone marrow transplant animals. 
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Figure 7: 
7a: 
 
Comparison of times to thrombosis between WT and CD39-TG baseline versus WT into WT and 
CD39-TG into WT platelet transfer experiments when Tyrode’s buffer containing 1 mM calcium 
was used to isolate and purify platelets.  WT baseline: (12.69 ± 2.17 min, n = 5), WT into WT: 
(11.21 ± 1.58, n = 5), CD39-TG baseline: (665.00 ± 24.50 min, n = 3), CD39-TG into WT: 
(179.90 ± 34.70 min, n = 5). 
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7b: 
 
Time plot showing percentage flow of initial following ferric chloride induced vessel injury 
(ferric chloride applied for 3 minutes starting at Time = 0) for WT into WT platelet transfer and 
CD39-TG into WT platelet transfer experiments when buffer containing 1 mM calcium was used 
to isolate and purify platelets.    
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Figure 8: 
8a: 
 
Comparing the times to thrombosis between WT into WT platelet transfer, CD39-TG into WT 
platelet transfer and WT baseline when Tyrode’s buffer void of calcium was used to isolate and 
purify platelets.  No significant difference between groups.  WT into WT: (11.53 ± 0.62 min, n = 
4), CD39-TG  into WT: (9.43 ± 0.83 min, n = 4), WT baseline: (12.69 ± 2.17 min, n =5). 
 
  
p = ns 
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8b: 
 
Time plot showing percentage flow of initial following ferric chloride induced vessel injury 
(ferric chloride applied for 3 minutes starting at Time = 0) for WT into WT platelet transfer and 
CD39-TG into WT platelet transfer experiments when buffer void of calcium was used to isolate 
and purify platelts. 
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